Symbols

CCCC

C4 Therapeutics·NASDAQ

--(--)

5.50 / 10

Netural

Analyst consensus is bullish (1 Buy, 1 Strong Buy) despite limited track record. Sentiment score 5.5 and fund‑flow score 7.53 (good) show solid capital inflows, especially from small‑, medium‑ and large‑size investors. Overall flow trend is mixed but net positive, supporting upside.

Fund Flow Rating

Analyst RatingStrong Buy

Wall Street Opinions

Strong Buy

50%

Buy

50%

Hold

Sell

Strong Sell

Date2026-02-27

InstitutionBarclays

Times predicted4

Historical Win Rate0.0%

Is money flowing into or out of CCCC?

CCCC holds a Bearish analyst rating, with 50% of experts assigning a Strong Buy grade. Factoring in net Outflows from order flow data, the comprehensive Sentiment Score stands at 5.50/10 (Netural).